How Tumor Mutational Burden Helps Predict Immunotherapy Response
In this blog, Caitlin Connelly discusses her research recently published in Genome Medicine predicting immunotherapy response and TMB as a potential biomarker.
Caitlin Connelly, Ph.D.
Caitlin Connelly is a scientist in the Cancer Genomics group at Foundation Medicine. Her work focuses on using molecular information from large genomic datasets to inform our understanding of cancer biology and to guide treatments.
Latest posts by Caitlin Connelly, Ph.D. (see all)
- How Tumor Mutational Burden Helps Predict Immunotherapy Response - 19th April 2017